Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
we are under pressure due to warrant conversions taking cash off the table .... it is not friggin rocket science ...
Rubbish they would issue debt ... evidently you haven't got a clue what you're talking about ..
Also utter rubbish , literally a few hundred thousand traded at 1.00 and under ... millions are being sold ...
utter rubbish we follow the XBI
Honestly, pack in the hero worship entropy b/s ..he`s the friggin warrant seller. HE NEVER SIGNED THE NDA( Bigger that is )
Merck m/c up $45bn in 6 weeks
Honestly, pack in the hero worship entropy b/s ..he`s the friggin warrant seller. HE NEVER SIGNED THE NDA
NO NO NO !! I meant Mr buyer Algoman ... not Mr seller Algoman for christ sake .. even the undead are against us ...
Mr Algo man... are you there ... are you there Mr Algo man ..
if you are send us a sign ... Mr Algoman... are you ....
Lykri . I think these current tweets are more directed at CLPT.
Flip , the only time she's speaks is when she's cornered in a room, ASM etc and even then every word has a safety net because she knows full well that whilst what she says could, happen it rarely if ever does.
So I think there's no way she`s saying ` Not SNO` in an 8K .
I think its really the data release, which of course if its released in a journal will be much more than just the normal 5 paragraph TLD template, and then global media.
The real question is , is the insistence of journal release because elements of the data is unclear and she is seeking peer ratification or so friggin good she wants the best possible platform....
BBC Main news coverage was very good on the JTM , so they know how to get it out there for sure.
Only additional positive I hang on to is Flaskworks was completely out of the blue (I know one poster suggested it as a good JV some months before ) but when it was announced I for one hadn't heard even the vaguest of rumours.
So maybe we get another `flaskworks` surprise.
I love an algo on the bid...
...they pre hedge , there’s no need to wait for the new shares to be issued before selling.
Option 2 def....
R/S to UPLIST. For heavens sake ..Ok you guys are the experts in this
I’ll back out …
Flipper this is the bit I do for a living r/s to uplist is a million miles from r/s to not go down.. trust me on this one thing
Les PLEASE R/S 25 for 1 and uplist to NYSE
I know you`ve done the prep.
Then the games will begin ...
We`d be at the current equivalent of $4-5 on day 1 and thats the kind of base to launch data from .. both price wise and exchange wise
Yep me too..
Dave Allen was Irish ... not from the UK
actually Kaizer I didnt say theyd told me that , everyone was depressed enough ...
Yep Shake bake with Sam Bakeman-Freid.... would be m/c $5bn on FTX within a week .. :)
Try this for size …
First spring in the NWBO step for a while.
This is apt :
Goodly news ...
Goodly News do I bring youth of forth
Kaiser , they said completely new applications can take longer than 90 days ...
TBH Woj, they told me sod all and would only speak about the process
Ha , we have a great many American's a hand full of English and Dutch , I wondered if we had any Irish representation !
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
PR Newswire
BETHESDA, Md., Oct. 28, 2021
BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.
First, a license to work with human tissues for medical products at Sawston has been issued by the UK Human Tissue Authority (HTA) to the Company's contract manufacturer and operator of the facility, Advent BioServices. Second, the comprehensive regulatory inspection of the facility has been conducted by the UK Medicines and Health Products Regulatory Authority ("MHRA").
In the UK, an HTA license is required for the collection, processing and storage of human tissues and cells for medical purposes. This includes the tumor tissues used to prepare the lysate for DCVax-L products, and the immune cells that comprise the active ingredient of DCVax-L. Obtaining such a license requires an application, inspection and certification process. This process has now been completed and the HTA license allowing the relevant activities to be conducted at Sawston for DCVax-L has been issued.
The Sawston facility must also be certified and licensed by MHRA in order to be able to manufacture products such as DCVax-L. The process involves an extensive application process, comprehensive inspection of all aspects of the physical facility, its construction and equipment, and all aspects of the facility's operations, including all operating systems, flow of materials and activities, sterility, quality control, staffing and other factors. It also includes extensive scrutiny of the quality management system that comprises approximately 1,000 regulatory documents, including standard operating procedures (SOPs) for the facility and for the product, validation records, data from practice manufacturing runs and other required documents.
Intensive preparations have been under way all year for this comprehensive inspection. A detailed application package and data were submitted to MHRA to qualify for the inspection. The original inspection timing was delayed by MHRA due to their caseload; however, the week-long onsite review by two MHRA inspectors was recently completed. The final phase of the process involves receiving an official MHRA inspection report and taking any responsive actions that may be required. The Company currently anticipates that this process will be completed before year-end.
Jed ,
Póg mo thóin
Algo buying all the way up..
5k sold at 1.01...looks like our `friendlies` really aren`t that friendly at all...
Its an indicator that the current share price is over sold .
close to 30 over sold , close to 70 overbought .
If the price doesnt bounce and we hang around the 1.03 ish level for a few days you`ll see the RSI start to rise , indicating to no longer expect a bounce.
RSI Closed Sub 30
I saw Senti warned us of more expiries up till 2nd November , I don`t know how many she alluded to but that will be the deciding factor
Captain - just over 20M shares have traded since the 25m step up in share out from 20th .
Volumes have just about doubled so, in theory 50%-60% of converts have been sold, which is fair enough for those involved, hopefully the selling will abate...
well done Nick you'll do well ..
RSI 29.7 ...bounce will come
Which date was the 20m warrant conversion please ?
HTA Licence –
The Human Tissue Authority (HTA) ensures that procurement, testing, processing, distribution and export of tissue and cells for human application is performed in accordance with the quality and safety standards of EU Directive 2004/23/EC
Patients adipose tissue are harvested under Human Tissue Authority (HTA) licenced procurement procedure, in a CQC registered hospital and manufactured under a The Medicines and Healthcare products Regulatory Agency (MHRA) licenced GMP cleanroom facility , Royal Free NHS
Lab Processing / Manufacturing – MHRA Licence
MHRA Licence –
The manufacturing step to obtain adipose derived stem cells and returning them to a patient for medicinal purposes falls under the Medicines and Healthcare Products Regulatory Agency (MHRA). To make human medicines, providers require a manufacturer licence, issued by the MHRA. To qualify for a manufacturer licence providers need to demonstrate to the MHRA compliance with EU good manufacturing practice ( GMP ) and pass regular GMP inspections.